From:  Targeting MAPK9 in neurodegenerative diseases: mechanistic insights, phytochemical modulators, and emerging computational approaches

 Neurodegenerative diseases associated with MAPK9 dysregulation.

Neurodegenerative diseaseRole of MAPK9 (JNK2)Major pathological mechanismsKey outcomes
Alzheimer’s disease (AD)Increased MAPK9 activation in response to amyloid β accumulation and oxidative stressAmyloid β toxicity, tau hyperphosphorylation, neuroinflammation, synaptic dysfunctionCognitive decline, neuronal loss, memory impairment [51]
Parkinson’s disease (PD)MAPK9-mediated apoptosis of dopaminergic neuronsα-Synuclein aggregation, mitochondrial dysfunction, oxidative stress, and neuroinflammationDopaminergic neuronal degeneration, motor dysfunction
Huntington’s disease (HD)Activation by mutant huntingtin-induced cellular stressOxidative stress, mitochondrial impairment, apoptotic signallingStriatal neuron degeneration, cognitive and motor deficits [66]
Ischemic brain injuryRapid activation following cerebral ischemia and reperfusionExcitotoxicity, oxidative stress, inflammatory cytokine release, apoptosisNeuronal death and neurological impairment [67]
Vascular dementiaMAPK9 contributes to inflammation and ischemic neuronal damageChronic cerebral hypoperfusion, endothelial dysfunction, blood-brain barrier disruption, oxidative stress, neurovascular inflammation, and MAPK9-mediated apoptosisCognitive impairment and neuronal dysfunction [68]
Multiple sclerosis (MS)MAPK9 participates in inflammatory and demyelinating processesImmune cell activation, cytokine production, oxidative stressDemyelination and neurodegeneration [69]
Frontotemporal dementia (FTD)Dysregulated MAPK9 signalling is associated with protein aggregation and neuronal lossTau pathology, neuroinflammation, apoptotic signallingBehavioural and cognitive dysfunction [70]

MAPK9: mitogen-activated protein kinase 9; JNK2: c-Jun N-terminal kinase 2.